Learn More
PURPOSE The impact of interferon beta (IFNβ) therapy on a patient's quality of life (QoL) has not been completely clarified. This multicenter, independent, observational and longitudinal study was aimed to evaluate the impact of different pharmaceutical formulations of IFNβ-1a on QoL in patients affected by relapsing-remitting multiple sclerosis (RRMS). (More)
The Functional Assessment of Multiple Sclerosis (FAMS) quality of life (QoL) instrument is a disease-specific, self-report questionnaire that was developed originally for US English-speaking patients. Here, the psychometric properties of the FAMS QoL questionnaire for Italian-speaking patients with multiple sclerosis (MS) are evaluated and compared with the(More)
The aim of this study was to assess the reliability, validity and sensitivity of the Guy's Neurological Disability Scale (GNDS) translated into Italian and administered to Italian-speaking patients with multiple sclerosis (MS). In total, 202 outpatients with MS were enrolled in the study; 153 had relapsing-remitting (RR) MS and 49 had secondary progressive(More)
Multiple sclerosis is a frequent neurologic disease, which causes sensory impairment, fatigue, cognitive deficits, imbalance, loss of mobility, spasticity, and bladder and bowel dysfunction. Several new therapies have been introduced in the past decade, but additional drugs are needed to slow disease progression and reduce disability. Natalizumab (NA) is an(More)
Background: The most suitable setting of rehabilitation for Persons with Multiple Sclerosis (PwMS) has not been identified so far because there is a general lacking of controlled studies. Aim of this study was to evaluate the treatment efficacy in terms of functional independence between two different settings. Methods: A randomized, wait-list controlled(More)
  • 1